Interleukin-27 in Tuberculosis: A Sheep in Wolf's Clothing?

Kristina Ritter[1], Jasmin Rousseau[1] and Christoph Hölscher[1,2]*

[1] Infection Immunology, Research Centre Borstel, Borstel, Germany, [2] German Centre for Infection Research (DZIF), Partner Site Hamburg-Borstel-Lübeck-Riems, Borstel, Germany

In tuberculosis (TB), protective inflammatory immune responses and the pathological sequelae of chronic inflammation significantly depend on a timely balance of cytokine expression. In contrast to other anti-inflammatory cytokines, interleukin (IL)-27 has fundamental effects in experimental *Mycobacterium tuberculosis* (Mtb) infection: the absence of IL-27-mediated signalling promotes a better control of mycobacterial growth on the one hand side but also leads to a chronic hyperinflammation and immunopathology later during infection. Hence, in the context of novel host-directed therapeutic approaches and vaccination strategies for the management of TB, the timely restricted blockade of IL-27 signalling may represent an advanced treatment option. In contrast, administration of IL-27 itself may allow to treat the immunopathological consequences of chronic TB. In both cases, a better knowledge of the cell type-specific and kinetic effects of IL-27 after Mtb infection is essential. This review summarizes IL-27-mediated mechanisms affecting protection and immunopathology in TB and discusses possible therapeutic applications.

Keywords: cytokines, tuberculosis, IL-27, protection, pathology

INTRODUCTION

Tuberculosis (TB) is an infectious bacterial disease caused by *Mycobacterium tuberculosis* (Mtb) that has challenged humanity for millennia (1). The industrial revolution in the 18th and 19th century, provided the basis for TB to reach epidemic levels in North America and Europe (1, 2). Although it can be assumed that the genus *Mycobacterium* originated more than 150 million years ago (3) TB was until then a rather rare endemic disease (2). Albeit Benjamin Marten suspected the infectious origin of TB as early as 1720, it was not until 1882 that Robert Koch was able to isolate the bacillus and provide evidence of Mtb as causative agent for TB in laboratory animals (1, 4). Since then, the successful treatment of TB has been a central topic in medicine.

With the discovery of streptomycin as an effective remedy for TB in 1944, it quickly became clear that the administration of a single antibiotic alone leads to rapid development of resistance (5, 6). This first demonstration of the requirement of a multi drug therapy, led to the arrival of the modern era of anti-TB chemotherapy with the elaboration of the standardized first-line TB treatment regimens that are still used today (6–8). However, since treatment regimens were developed decades ago, therapy of TB has remained largely unchanged (9). Nevertheless, TB remains a major public health problem with estimated one-quarter of the world's population infected by Mtb leading to 1.4 million deaths in 2019 and the need for improved treatment and vaccination strategies is urgent (10).

Adjunctive host-directed therapies (HDT) modulating host immune pathways during antibiotic treatment are in the focus of TB research because such a type of treatment could shorten therapy time, increases efficacy and overall prevent the development of drug resistance (11, 12). However, only understanding of the pathophysiological molecular mechanisms underlying the interplay between Mtb and the host's immune system will provide a rational basis for the development of more effective and optimized regimens to combat and prevent this ancient disease.

Mtb is transmitted from person-to-person by the inhalation of infectious aerosolized droplets exhaled by people with active TB (13, 14). The bacteria have developed strategies to avoid the elimination and can replicate within macrophages (MΦ). This induces the production of cytokines and chemokines by infected MΦ leading to the accumulation of infected MΦ, neutrophils, monocytes, and dendritic cells (DC) at the infection site resulting in the formation of a granuloma (13, 15, 16). Granulomas are complex structures that concentrate immunological responses, restrain Mtb and prevent dissemination to other organs. In response to Mtb infection, most infected individuals mount an immune response, that is only partially effective and rarely completely eradicate the bacteria (13). However, active TB develops when these initial granulomatous lesions lose their capability to contain mycobacterial replication.

In the regulation and orchestration of the inflammatory response against Mtb infection and the subsequent balance between protection and immunopathology cytokines play a key role (17). Especially, pro-inflammatory cytokines produced by T helper (Th)1 [e.g. interferon-gamma (IFNγ)] and Th17 [e.g. interleukin (IL)-17A] cells are considered to be the main effector cytokines mediating subsequent protective immune functions important for controlling Mtb infection (18, 19). However, although pro-inflammatory cytokines are necessary for host protection against Mtb, they can also promote the development of immune-mediated pathological consequences in the lung (20).

Especially, the extent of importance of IFNγ in the protection against TB is currently debated due to a lack of correlation between IFNγ-levels and the degree of protection (21–23). In fact, IFNγ-deficiency in the murine model results in higher bacterial loads leading to decreased survival in the course of Mtb infection, whereas overproduction of IFNγ is accompanied by increased lung pathology and as a consequence also fatal to the host (24–27).

Another pro-inflammatory cytokine that is also closely associated with protective and pathological functions in TB is IL-17A (28). After experimental infection with Mtb, IL-17A is involved in the formation and stability of granulomas by promoting neutrophil recruitment and chemokine release (29, 30). On the other hand, during chronic TB IL-17A-mediated extensive neutrophil recruitment and persistent inflammation are associated with tissue damage and immunopathology (28, 30).

In contrast to these pro-inflammatory cytokines, inhibitory and anti-inflammatory cytokines exhibit immune-limiting mechanisms in TB. First of all, IL-10 appears to be a very important anti-inflammatory cytokine, since several studies in different infectious diseases demonstrated that the absence of IL-10 results in stronger Th1 immune responses accompanied by improved pathogen clearance (31–34) but eventually also in accelerated and fatal hyper-inflammation (35, 36). However, after Mtb infection IL-10-deficiency has only a very limited impact on protection and no effect on immunopathology (34, 37). Only on a susceptible genetic background the absence of IL-10 was accompanied by improved effector mechanisms (38). But when overexpressed, IL-10 impaired protective immune responses with decreased levels of IFNγ and IL-17A, alternative MΦ activation and the establishment of chronic infection (34, 39–41).

Compared to IL-10, IL-27 appears to play a far more important role as an anti-inflammatory cytokine during experimental TB. Although initially reported as required for mediating the differentiation of Th1 cells (42–44), subsequent work revealed that IL-27 is involved in regulating Th1, Th2 and Th17 immune responses (45–47). In the context of Mtb, the lack of the IL-27 receptor-alpha (Rα) chain in experimental mice resulted in decreased bacterial loads associated with increased Th1 and Th17 immune responses and improved granuloma formation (30, 48). Although IL-27Rα-deficient (-/-) mice exhibited better control of Mtb, the detrimental higher production of pro-inflammatory cytokines resulted in a hyperinflammatory systemic immune response and accelerated death (48). In this regard, IL-27 represents a 'double-edged sword' as it mediates both protective and pathological immune responses to Mtb infection (30, 48). This review therefore considers the possible mechanisms underlying this central immunoregulatory function of IL-27 in TB and suggests possible aspects of therapeutic and preventive applications.

IL-27 AND THE IL-27 RECEPTOR

IL-27, which was first described in 2002, is a member of the IL-6/IL-12 cytokine family (49–51). It forms a heterodimeric complex comprising of the α–subunit IL-27p28, a four-α-helix bundle protein, and the β subunit Epstein-Barr virus-induced gene 3 (EBI-3), which is structurally related to soluble receptors of this cytokine family (**Figure 1**). IL-27 is released by activated MΦ and DC (50, 52). Its signal transduction occurs through binding to a heterodimeric receptor complex consisting of the specific subunit IL-27Rα [formerly known also as WSX-1 or TCCR (T cell cytokine receptor)] and the ubiquitous gp-130 subunit (53) (**Figure 1**). The IL-27R is expressed on various immune cells but most notably on T cells, MΦ, and DC (**Figure 1**). The binding of IL-27 to its receptor complex leads to the phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3 *via* the activation of various kinases (**Figure 1**). According to the STAT1 pathway, IL-27 was initially assigned pro-inflammatory properties, as it induces T-box expressed in T cells (T-bet) and the expression of a

FIGURE 1 | IL-27 and the IL-27R. The gp130 cytokine IL-27 is a heterodimeric cytokine comprising of a secreted receptor α-subunit and four-helix bundle protein (IL-27p28/EBI-3). The receptor complex for IL-27 contains gp130 and the IL-27R subunit-α, which is structurally similar to gp130. The intracellular domains of the receptor complex associate with the Janus kinases JAK1, JAK2 and Tyrosine kinase (TYK)2. IL-27-induced conformational changes of the receptor complex activate JAK1/TYK2 or JAK1/JAK2 and initiate a phosphorylation cascade that leads to the activation of signal transducer and activator of transcription (STAT)1 or STAT3, respectively. The IL-27R is predominantly expressed on T cells, MΦ and DC where the Il-27R-mediated activation of STAT1/3 differentially affects the production of cell-type specific transcription factors.

functioning IL-12 receptor complex in naive CD4$^+$ T cells whereby it instructs Th0 cells to develop a Th1 program (43, 46, 53, 54) (**Figure 1**). In contrast to this pro-inflammatory function during the early phase of a cell-mediated immune response, IL-27 mediates anti-inflammatory effects primarily *via* the phosphorylation of STAT3 (48, 55, 56). Basically, IL-27 can limit the strength and duration of Th1, Th2 and Th17 immune responses either directly or indirectly. It dampens overshooting Th1 cells and ameliorates corresponding type 1 inflammatory diseases (45, 48). Excessive Th2 and Th17 immune responses can be controlled by IL-27 through the downregulation of the transcription factors GATA3 (GATA binding protein 3) and retinoid-related orphan receptor gamma t (RORγt), respectively (46, 57, 58) (**Figure 1**). IL-27 can also indirectly regulate cell-mediated immune responses and excessive inflammatory reactions by promoting regulatory T$_{reg}$ and Tr1 cells. It induces central molecules in T$_{reg}$, which are essential for the function of these cells (59, 60). While the underlying mechanisms of this IL-27-dependent activation of T$_{reg}$ are still largely unclear, it has been described for Tr1 cells that IL-27 mediates IL-10 production *via* the induction of the transcription factor c-MAF (61, 62) (**Figure 1**). But IL-27 does not only intervene in cell-mediated immune responses at the level of T lymphocytes. It can also inhibit the inflammatory

reaction in activated MΦ and DC and thus indirectly control the development of Th1 and Th17 cells by reducing the release of IL-12, IL-6 and IL-23 (48, 63–65).

THE DUAL IMPACT OF IL-27 DURING TB

During Experimental TB, IL-27 Limits Protective Immunity but Also Prevents From Immunopathology Caused by Excessive Inflammation

Past *in vivo* studies on the role of IL-27 during TB focused on the analysis of mice with a constitutive deficiency in the private IL-27R domain IL-27Rα (IL-27Rα$^{-/-}$) (30, 48, 66, 67). After infection with Mtb, these mice exhibit increased levels of the pro-inflammatory cytokines TNF and IL-12 followed by an enhanced activation of CD4$^+$ T cells in the lung, which eventually culminates in reduced bacterial burdens (48). By reconstitution of lethally irradiated TCRβδ$^{-/-}$ mice with IL-27Rα$^{-/-}$ or intact bone marrow (BM), respectively, it was further demonstrated that T cells deficient in IL-27Rα are better able to control mycobacterial loads, indicating that the absence of IL-27Rα specifically on T cells accounts for the increased protection (67) (**Figure 2**). In the late phase of infection, however, IL-27Rα$^{-/-}$ mice also suffer from uncontrolled chronic hyper-inflammatory immune responses accompanied by excessive systemic production of pro-inflammatory cytokines (48) (**Figure 2**). In consequence, in the later stages of Mtb infection, the animals develop secondary inflammatory symptoms. These include lung-specific advanced inflammatory cell infiltration accompanied with interstitial fibrosis, and deposition of cholesterol crystals (**Figure 2**) but also systemic pathological sequelae as splenomegaly, cachexia, and eventually shortened survival. Thus, IL-27 represents an important regulator during experimental TB with a dual function. On the one hand, the cytokine suppresses protective immunity in Mtb-infected mice, leading to a compromised mycobacterial containment (30, 48, 66), however, it also contains the pathological sequelae of chronic systemic inflammation (30, 48).

A hallmark of the host defence against mycobacterial infection constitutes the formation of granulomas (68). After infection with Mtb, alveolar MΦ express various inflammatory signals, such as TNF and the chemokines C-X-C motif ligands (CXCL)9 and 10, which mediate the recruitment of innate and adaptive immune cells to the sites of infection (69, 70). The resulting mature granuloma builds a microenvironment that brings effector T cells in close proximity to infected MΦ to optimally mediate mycobacterial killing (68). Importantly, also B cells aggregate within follicle-like structures around lung granulomas (71–74), which appear to contribute to granuloma organization and enhance protective immunity against TB (73). During experimental TB, IL-27 appears to have a negative impact on the architecture of lung granulomas and the localization of antigen-specific T cells (30, 67). Accordingly, Mtb-infected IL-27Rα$^{-/-}$ mice at first develop a very efficient granulomatous response in the lung (30, 48) (**Figure 2**). In contrast to C57BL/6 mice, which show rather unstructured granulomatous lesions

FIGURE 2 | IL-27 in experimental TB and its protective and pathological immune responses at different states of Mtb infection. IL-27, produced by DC or MΦ in response to infection with Mtb, acts on various cell types. It controls the accumulation of PD1[+] CD4 T cells in the lung parenchyma and limits the expansion of IL-17A-producing Th17 cells either directly or indirectly by increasing the numbers of T_{reg} or inhibiting the production of the Th17-driving cytokines IL-6 and IL-23 by DC and MΦ. Thereby, defending mechanisms as infiltration of the lung tissue with PD[+] CD4[+] T cells, the chemokine-mediated formation of protective granulomas, the recruitment of B cells and IFNγ/TNF/IL-2-producing multifunctional (Muf) T cells as well as subsequent MΦ activation are diminished by IL-27. However, even if IL-27 suppresses these protective functions, during later states of infection it also controls lung-specific advanced inflammatory cell infiltration and interstitial collagen deposition but additionally systemic cytokine levels and eventually premature death.

upon Mtb infection, granulomas in IL-27Rα[-/-] mice are highly stratified containing a centre of infected MΦ surrounded by a pronounced rim of B and T lymphocytes (30). In contrast to these well-structured protective granulomas, however, moribund IL-27Rα[-/-] mice in the late phase of chronic infection exhibit deconstruction of the granulomatous organization (48). As mentioned above, during this stage of infection, lungs show an accelerated tissue pathology connected to an overflowing pro-inflammatory cell infiltration, interstitial fibrosis and deposition of cholesterol crystals.

In addition to the histological differences, T cells in Mtb-infected IL-27Rα[-/-] mice exhibit an altered phenotype and a modified cytokine expression pattern (30, 67). Accordingly, during chronic Mtb infection, lung CD4[+] T cells in these mice are characterized by a decreased expression of the Th1 transcription factor T-bet and the killer cell lectin-like receptor G1 (KLRG1), while they maintain the phenotypic markers programmed death-1 (PD-1), CD69 and CD127 (67). In

experimental TB, high expression levels of KLRG1 are claimed to identify a population of terminally differentiated effector CD4[+] T cells (75). These cells are characterized by a high secretion of IFNγ along with a short life span and a low proliferative capacity. After vaccination against Mtb, the induction of antigen-specific KLRG1[-] IL-2-producing CD4[+] T cells, in contrast to KLRG1[+] T cells, correlate with increased protection (76). PD1[+] CD4[+] T cells, on the other hand, represent an essential pool of activated self-renewing effector T cells which still bear the capacity to further differentiate into antigen-specific effector cells (75). Together, IL-27 seems to adversely affect the fitness of lung effector CD4[+] T cells during experimental TB.

The presence of IL-27 during experimental TB furthermore affects the cytokine expression profile of T cells in the lung (30). Thus, so-called multifunctional CD4[+] (Muf) T cells, which simultaneously express the cytokines IFNγ, TNF and IL-2, strongly accumulate in the lungs of Mtb-infected IL-27Rα[-/-] mice (**Figure 2**). Muf T cells represent an effector T cell population with superior properties when compared to single cytokine-producing T cells (77–80). During Mtb infection, IFNγ and TNF appear to act synergistically to activate antimicrobial mechanisms in infected MΦ (79, 81, 82). Besides, the expression of IL-2 in CD4[+] T cells enhances their competitiveness for long-term survival (83). When compared to single-cytokine-producing CD4[+] T cells, Muf T cells have also been demonstrated to exhibit higher cytokine production levels on the single-cell level (30, 78, 80). In models of vaccination against Mtb, the induction of Muf T cells correlates with antimycobacterial protection (78, 80). Importantly, in contrast to the induction of Muf[+] T cells, the overall frequencies of IFNγ-producing CD4[+] T cells are not influenced by the absence of IL-27Rα-mediated signalling (30). By use of a C57BL/6 and IL-27Rα[-/-] mixed BM chimera model, it has, on the other hand, been shown that the capacity to produce IL-2 is generally highly improved in IL-27Rα[-/-] antigen-specific CD4[+] T cells (67). In addition to the increased expression of IL-2, caspase activity in CD4[+] T cells also appears to be markedly reduced in Mtb-infected IL-27Rα[-/-] mice, pointing at lower susceptibility to cell death (67). Whereas T cell longevity therewith seems to be increased in the absence of IL-27-mediated signalling, conflicting data exist regarding the anti-proliferative activity of IL-27 in the context of Mtb infection (48, 67). In conclusion, the here described findings indicate that during experimental TB, CD4[+] T cells in an IL-27Rα-deficient environment are characterized by their improved longevity and enhanced effector properties reasoned by the simultaneous expression of the cytokines IFNγ, TNF and IL-2.

The efficiency of antimycobacterial effector T cell responses is not only determined by their fitness and intrinsic qualities, but also by their localization near infectious pulmonary lesions. Upon Mtb infection, protective PD-1 and CXCR-3 expressing T cells are better able to infiltrate into the lung parenchyma, whereas IFNγ-expressing KLRG1[+] terminally differentiated effector CD4[+] T cells accumulate within lung blood vasculature (84, 85). In accordance with this finding, in Mtb-infected IL-27Rα[-/-] mice the lower frequency of KLRG1[+] CD69[-] T-bet[hi] CD4[+] T cells results in a higher proportion of antigen-specific T cells within the lung parenchyma (67). Importantly, this

parenchymal accumulation of CD4$^+$T cells in the absence of IL-27Rα is also connected to an augmented colocalization of these cells with Mtb-antigen (67). Accordingly, Mtb-infected IL-27Rα$^{-/-}$ mice exhibit enhanced MΦ activation reflected by increased gene expression levels of the antimicrobial molecules nitric oxide synthase-2 (NOS2) and IFNγ-dependent GTPase LRG-47 (48) (**Figure 2**). In the highly organized granulomas observable in IL-27Rα$^{-/-}$ mice, T cells preferentially accumulate in the outer rim in proximity to the afore-mentioned B cell areas (30) (**Figure 2**). In this context, further investigation may reveal the relevance of B cell-mediated signals for the migratory capacity of protective CD4$^+$ T cell within the Mtb-infected lung. Altogether, IL-27 seems to impede the ability of CD4$^+$ T cells to assess the lung parenchyma to eventually hinder the direct association of effector T cells with infected phagocytes in lung lesions.

As mentioned before, IL-27 has been demonstrated to inhibit the development of Th17 immune responses in various mouse models of chronic inflammation (47, 58, 86, 87). Importantly, higher frequencies of IL-17A-expressing Th17 cells were also observed in the lungs of Mtb-infected IL-27Rα$^{-/-}$ mice (30). By use of IL-27Rα$^{-/-}$ mice with an additional deficiency for IL-17A, the impact of this increased production of IL-17A in the absence of IL-27-mediated signalling was therefore further investigated. The obtained data revealed that IL-17A mediates to a large extent the enhanced protection in the IL-27Rα-deficient environment, but on the other hand, it also triggers the exacerbated immunopathology in Mtb-infected IL-27Rα$^{-/-}$ mice (**Figure 2**). On the immunological level, IL-17A does not seem to exert any impact on the proportion of KLRG1$^+$ CD4$^+$ T cells, however, it mediates the accumulation of Muf T cells in the lungs of IL-27Rα$^{-/-}$ mice (**Figure 2**). Moreover, the generation of highly stratified granulomas in the Mtb-infected IL-27Rα$^{-/-}$ mice is strikingly dependent on IL-17A, which is not surprising given that the impact of IL-17A on TB granuloma formation has been described before (29). In this context, IL-17A also supports the expression of the T cell-attracting chemokines CXCL9, CXCL10 and CXCL13 in the lungs of the infected IL-27Rα$^{-/-}$ mice (30) (**Figure 2**).

In conclusion, in the context of experimental TB, IL-27 functions as a key regulatory player with a dual impact on the outcome of Mtb infection. On the one hand, the cytokine hampers bacterial containment as well as the formation of highly organized protective granulomas in the lung, however, in the late phase of infection it also prevents from chronic hyper-inflammation and immunopathology (30, 48). It appears likely that IL-27-mediated – direct or indirect - effects on CD4$^+$ T cells fundamentally affect protection during TB. The cytokine has been demonstrated to exert influence on both the intrinsic fitness as well as protective quality of Mtb-specific T cells subsets and the localization of these cells (30, 67). Importantly, the suppressive effect of IL-27 on the expression of the pro-inflammatory cytokine Il-17A also plays an central role, as, in the absence of IL-27Rα the cytokine affects both protective immunology but also immunopathology (30). However, as IL-27 constitutes a pleiotropic cytokine with IL-27R being expressed on various cell types, potential cell type-specific effects on other adaptive and myeloid cell subsets also need to be taken into consideration as discussed hereinafter. Future investigation may also put additional focus on the kinetic analysis of protective and deleterious effects mediated by IL-27. A better knowledge of both the cell type-specific and kinetic effects of IL-27 during Mtb infection is essential to evaluate potential therapeutic implementations for the management of human TB.

From Mice to Men: IL-27 in Human TB and Potential Limitations of Experimental Studies

During human TB, increased levels of IL-27 are associated with active disease (67) and expression of both the IL-27p28 and EBI3 subunit was noticed in human TB granulomas (88). Moreover, TB pleural effusions also exhibit increased amounts of IL-27, pointing at a potential usage of the cytokine as a biomarker to differentiate between TB pleural effusions and other causes of pleural effusions (89, 90). Sources of IL-27 in TB pleural effusions appear to be monocytes, MΦ, B cells, both CD4$^+$ and CD8$^+$ T cells, NK/NKT cells as well as mesothelial cells (89). Notably, human TB pleural effusions were shown to contain a specific subset of terminally differentiated IL-27-secreting CD4$^+$ T cells with a unique expression profile of pro-inflammatory cytokines, which may perform important functions in TB immunity through the interference with pleural mesothelial cells (91). Another study, however, identified gene polymorphisms associated with a pronounced reduction of IL-27 in individuals with pulmonary TB (92).

The enhanced expression of IL-27 during human active TB (67) underlines the relevance for investigating the role of the cytokine in the context of TB and is consistent with the improved mycobacterial containment in IL-27Rα$^{-/-}$ mice (48, 66). Although Mtb infection studies in mice with a constitutive or conditional deficiency of IL-27Rα can provide crucial insights into mechanisms of action and functions mediated by IL-27, data thus obtained subject to several limitations. First of all, further cytokines have been demonstrated to signal through IL-27R. Accordingly, in B cells, the heterodimeric cytokine IL-35 signals through IL-27Rα and IL-12Rβ2 (93). IL-35 consists of EBI-3 and IL-12p35 and was demonstrated to have suppressive functions (94). Additionally, IL-27R, together with gp130 and IL-6Rα, forms a receptor for a heterodimer consisting of IL-27p28 and cytokine-like factor (CLF) (95). Furthermore, the absence of IL-27Rα may generally interfere with the balance between the cytokine subunits (67). Finally, other factors such as the route of exposure and the bacterial dose might have an impact on the experimental outcome. The combination of findings generated by experimental and human TB studies may therefore help to constitute a precise view of the IL-27-mediated immune mechanisms.

TARGET CELLS OF IL-27 DURING TB: WHO ARE THE PIVOTAL PLAYERS?

The broad expression of IL-27R on different cell types partially accounts for the complex regulatory functions IL-27 exerts in the

context of infectious diseases (48, 63). As described before, *in vivo* studies figured out that protective immunity to Mtb infection in the IL-27R-deficient environment is substantially mediated through the intrinsic modulation and differential localization of effector CD4[+] T cell populations (30, 48, 67). However, to obtain a more complete picture of the IL-27-mediated mechanisms affecting both protection and immunopathology in TB, it is important to additionally highlight potential specific effects of IL-27 on various IL-27R-expressing target cells (**Table 1**).

In contrast to the enhanced frequencies of Th1 and Th17 cells, numbers of IL-17A-expressing γδ T cells - which appear to represent a first line of defence during the early immune response to Mtb (99) - are not affected by the absence of IL-27Rα in the lungs of Mtb-infected mice (30). Therewith, it is likely that Mtb-specific Th17 cells alone account for the increased secretion of IL-17A in these mice, which is, in turn, connected to both the improved protection and deleterious immunopathology (30) (**Table 1**).

As part of the Mtb-specific CD4[+] T cell immune response, IL-27 may - in addition to its regulatory influence on protective Th1 and Th17 cells - also exert influence on regulatory T cell subsets. As described before, IL-27 constitutes a potent promoter of IL-10-producing regulatory Tr1 cells (61, 62) and beneficially affects the functionality of T_{reg} (59, 60). In the context of experimental TB, T_{reg} accumulate at the infectious lesions, where they, in turn, may suppress protective immune responses against Mtb (100). Moreover, Mtb-specific T_{reg} delay the priming of effector CD4[+] and CD8[+] T cells in the pulmonary lymph node and eventually the onset of the adaptive immune response in the lung (101). Additionally, IL-10 was shown to attenuate protective antimycobacterial immune responses in both C57BL/6 and CBA/J mice (38, 40). Regarding the effect of IL-27-mediated signalling on regulatory T cell populations, reduced frequencies of Tr1 cells were found in the lungs of Mtb-infected IL-27Rα[-/-] mice (30) (**Table 1**). In the chronic phase of experimental TB, the accumulation of T_{reg} also tends to be impaired in the absence of

IL-27Rα (**Figure 2**, **Table 1**). Both effects, however, appear to occur independently of the elevated expression of IL-17A in IL-27Rα[-/-] mice (**Table 1**). Importantly, a detailed functional analysis on the direct impact of IL-27 on T_{reg}, has not been performed yet. To generate these data, Mtb-infected mice with a T_{reg}-specific deficiency of IL-27Rα constitute a suitable experimental model.

Along with CD4[+] T cells, CD8[+] T cells appear to also contribute to containment of both the initial and long-term infection with Mtb (102). Especially, many assume that the simultaneous induction of both CD4[+] and CD8[+] T cells is fundamentally important in the context of efficient novel vaccination strategies against TB (103–105). In the absence of IL-27Rα, higher numbers of CD8[+] T cells accumulate in the lungs of Mtb-infected mice (48) (**Figure 2**, **Table 1**). Additionally, these CD8[+] T cells also exhibit enhanced expression of activation markers. Activated lung CD8[+] T cells may therefore also be a part of the improved antimycobacterial immunity in IL-27Rα[-/-] mice, eventually resulting in a more efficient containment of Mtb.

As mentioned before, in the absence of IL-27Rα, Mtb-infected lungs exhibit highly structured granulomas surrounded by a lymphocyte rim which predominantly contains clusters of B cells - an effect that is strikingly dependent on the expression of IL-17A (30) (**Figure 2**, **Table 1**). Although the role of these B cell clusters is not yet fully understood, it was demonstrated that in B cell-deficient mice reduced containment of mycobacterial loads correlates with an altered granulomatous response (73). Importantly, the accumulation of B cells in secondary lymphoid structures within in the peripheral rim of granulomas is also observable during human TB (106, 107).

The early establishment of Mtb infection is crucially determined by cells of the innate immune system (108, 109). Antigen presenting cells (APC), such as MΦ and DC, are able to initiate granuloma formation and adaptive immunity by the presentation of antigen and the secretion of pro-inflammatory

TABLE 1 | Direct and indirect effects of IL-27-mediated signalling on different immune cell populations in the context of TB.

Cell type	Impact of IL-27[1]	Through suppression of IL-17A?[2]	Detailed description[1]
Th1	↓	–	Altered phenotype (enhanced numbers of KLRG1[+] terminally differentiated CD4[+] T cells) (67)
			Reduced accumulation of protective PD-1[+] CD4[+] T cells in the lung parenchyma (67)
Muf T	↓	+	Reduced frequency in the lung (30)
Th17	↓		Reduced frequency in the lung (30)
Tr1	↑	–	Enhanced frequency in the lung (30)
T_{reg}	↑	–	Slightly enhanced frequency in the lung (30)
CD8[+] T cells	↓	not described	Reduced frequency in the lung (48)
B cells	↓	+	Reduced localization at granulomatous lesions (30)
MΦ	↓	not described	Suppression of pro-inflammatory cytokine release (48)
			Inhibition of phagosomal acidification (96, 97)
			Inhibition of IFNγ-mediated autophagy (98)
neutrophils	↓	+	Reduced localization at granulomatous lesions (not connected to impaired protection, but potentially to reduced immunopathology) (30)

[1]*Summary of findings obtained from in vivo studies in Mtb-infected IL-27Rα[-/-] mice as well as in vitro studies in Mtb-infected murine and human MΦ;* [2] *Findings obtained from investigation of Mtb-infected IL-27Rα[-/-]/IL-17A[-/-] mice (30); ↓ suppressive impact of IL-27-mediated signalling; ↑ promoting impact of IL-27-mediated signalling; – effect mediated by IL-27 in an IL-17A-independent manner; + effect mediated by IL-27 through suppressing IL-17A production in CD4[+] T cells.*

cytokines, but on the other hand, they also create the primary niche for Mtb replication (108). Thereby, Mtb developed several mechanisms to escape from destruction within infected cells, including the blockade of phagosome maturation, regulation of autophagy and the restriction of antimicrobial peptide production. As IL-27R is known to be expressed on myeloid cells (42, 43, 48), IL-27 may also directly act on Mtb-infected MΦ (**Figure 2**, **Table 1**). Indeed, *in vitro* data demonstrate that IL-27Rα-mediated signalling directly affects the antimycobacterial activity in Mtb-infected murine and human MΦ (48, 97, 110). In murine IFNγ/LPS-stimulated or Mtb-infected peritoneal MΦ, the presence of IL-27Rα-mediated signalling suppresses the release of IL-12/23p40 and TNF, possibly through the concurrently observed induction of STAT3 phosphorylation (48, 111) (**Table 1**). Moreover, by incubation of human Mtb-infected MΦ with a soluble receptor to neutralize IL-27 (sIL27RA), it was shown that IL-27 antagonizes IL-18 activity by inhibiting the IL-18 receptor β-chain and blocking of NF-κB activation (110). IL-18, along with IFNγ and TNF, appears to play a critical role in the antimycobacterial activity of Mtb-infected MΦ when IL-27Rα-mediated signalling is blocked while IL-12 is supplied (112). Notably, upon stimulation of mouse BM-derived MΦ with LPS, IL-27 also triggers the production of the anti-inflammatory cytokine IL-10 *via* the activation of STAT1 and STAT3 (113). Together, these data indicate that IL-27 exerts differential impact on the secretion of pro- and anti-inflammatory cytokines from activated MΦ. The IL-27-dependent impaired release of Th1 and Th17-driving cytokines from Mtb-infected MΦ, in turn, compromises the development of protective T cell responses (**Figure 2**). In addition to these indirect MΦ-specific effects of IL-27 on protective immunity against Mtb, IL-27Rα-mediated signalling also appears to directly suppress antimicrobial effector mechanisms in the infected MΦ. Thus, in human MΦ, IL-27 interferes with the acidification of phagosomes and the subsequent process of phagosome-lysosome fusion by inhibiting the expression of vacuolar ATPase (V-ATPase) and lysosomal integrated membrane protein-1 (CD63) (96, 97) (**Table 1**). Additionally, the cytokine compromises the maturation of cathepsin D, which plays an important role for the degradation of mycobacteria and antigen processing within the cells (97, 114). It has also been described that IL-27 inhibits IFNγ-mediated autophagy through activation of the autophagy negative regulatory molecules mammalian Target of Rapamycin (mTOR) and Myeloid-cell leukaemia 1 (Mcl-1) to eventually avert the elimination of intracellular bacteria in Mtb-infected human MΦ (98) (**Table 1**). In conclusion, the outlined *in vitro* findings strongly suggest that IL-27 limits protective immunity against Mtb partially through its direct impact on infected MΦ. The relevance of a MΦ-specific deficiency of IL-27Rα on the outcome of Mtb infection, however, has not been experimentally tested yet. Instead, the effect of MΦ-specific lack of gp130 was investigated in the context of experimental TB (64). When compared to genetically intact control mice, MΦ-specific gp130-deficient mice express increased levels of Th17-driving cytokines and subsequently increased frequencies of IL-17A-producing cells yet do not exhibit any alteration in mycobacterial containment (64).

In contrast, in the absence of gp130 on T cells, bacterial burdens actually appear to be moderately increased but Th17 immune responses were not significantly affected (115). When assessing data obtained in these mouse models, however, compensatory effects caused by other gp130-dependent cytokines, such as IL-6, must be taken into consideration. IL-27 also exerts immunosuppressive influence on human and murine DC (116), however, to our knowledge this effect was not yet investigated in the context of Mtb infection.

A well described function of IL-17A is the recruitment of neutrophils, which appears, in the context of experimental TB, to be associated with the early development of granulomas (117). Accordingly, in Mtb-infected IL-27Rα[-/-] mice, IL-17A mediates the early accumulation of neutrophils in the centres of organized granulomas (30) (**Figure 2**, **Table 1**). Thereby, the anti-G-CSF induced reduction of neutrophils in the blood, however, does neither result in an altered granulomatous response nor in modified bacterial loads. This finding indicates that the protective role of IL-17A in the IL-27Rα-deficient environment is not mediated by its effect on the recruitment of neutrophils (**Table 1**). However, since high numbers of neutrophils are known to be associated with susceptibility in the chronic phase of TB (118, 119), the enhanced levels of neutrophils in the lungs of IL-27Rα[-/-] mice may contribute to the emerging immunopathology during late infection.

Together, both *in vivo* and *in vitro* data indicate that upon infection with Mtb, IL-27-mediated signalling may exert direct impact on different cell subsets of both the innate and adaptive immune response. A broader knowledge of the cell type-specific effects of IL-27 could therewith help to uncouple protective and immunopathological mechanisms mediated by the cytokine. To this end, mouse models which exhibit a conditional deficiency of IL-27R within a specific cell type represent a beneficial tool.

CONCLUDING REMARKS AND POSSIBLE APPLICATIONS

In the context of experimental TB, IL-27 turns out to be a sheep in wolf's clothing: Even though the cytokine significantly hampers optimal containment of Mtb in the lung, the cytokine eventually protects from pathological sequelae of chronic hyper-inflammation in the late stage of infection (48).

In vivo mouse data provide a comprehensive picture of the IL-27-mediated effects on the structure of lung granulomas as well as on the localization and intrinsic quality of effector CD4[+] T cell subsets during Mtb infection (30, 67). In this context, the IL-27-mediated suppression of pro-inflammatory Th17 cells appears to fulfil a major function (30). Accordingly, both the decreased bacterial burdens and the enhanced immunopathology in the absence of IL-27Rα are dependent on the expression of IL-17A. However, initial findings from *in vivo* and *in vitro* studies indicate that the pleiotropic cytokine IL-27 may also affect other innate and adaptive immune subsets during TB (30, 48, 96–98).

Although the role of IL-27 in TB is certainly complex, two possible strategies can be identified, of how a specific interference with IL-27-related immune mechanisms may improve novel therapeutic and preventive approaches. One the first hand, the improved control of mycobacterial growth in IL-27Rα$^{-/-}$ mice indicates that the timely restricted blockade of IL-27 might constitute an interesting future option in the context of novel HDT or vaccination strategies. This approach is further substantiated by the observed up-regulation of IL-27 in patients with active TB (67). Notably, a naturally occurring soluble form of IL-27Rα (sIL-27RA) has been described, which inhibits the binding of IL-27 to its cell surface receptor (120). Treatment with recombinant sIL-27RA, moreover, was demonstrated to be beneficial during septic peritonitis (121). So far, however, the impact of a timely administration of this inhibitor during primary Mtb infection or vaccination on the outcome experimental TB has not been investigated. A second treatment option, in contrast, would emphasize to dampen the exacerbated inflammation in late phase of chronic TB by administration of IL-27 itself, as indicated by the present mouse experimental data (48). In this context it may at first be important to consider that, although the continuous treatment with immunomodulatory drugs, such as TNF-antagonists, is linked to an increased risk of reactivated Mtb infection in patients with latent TB (122), anti-inflammatory therapeutics against TB can have beneficial effects when administered in combination with antibiotics during adjunct therapy (123). A contrary indication may certainly be the observation that up-regulation of IL-27 has been connected to the occurrence of immune reconstitution inflammatory syndrome (IRIS), a phenomenon which is observed in TB patients coinfected with HIV (67, 124). However, it is not yet known if the cytokine exerts any functional impact on the development of this inflammatory disorder. Generally, further experimental and human research is needed to clarify a potential usage of Il-27 in the context of immunomodulatory HDT approaches against chronic TB.

Altogether, the key to a safe and efficient therapeutic intervention with IL-27-related immune mechanisms in the context of anti-TB management may be the spatiotemporal uncoupling of the protective and immunopathological effects mediated by the cytokine and, eventually, a very specific usage of therapeutics on this background. Basic research may help to gain a more precise knowledge of the cell type-specific and kinetic effects of IL-27 after Mtb infection.

AUTHOR CONTRIBUTIONS

KR, JR, and CH contributed to conception of this review. KR and CH wrote the first draft of the manuscript. KR, JR, and CH wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

REFERENCES

1. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The History of Tuberculosis: From the First Historical Records to the Isolation of Koch's Bacillus. *J Prev Med hygiene* (2017) 58:E9–12.
2. Bates JH, Stead WW. The History of Tuberculosis as a Global Epidemic. *Med Clin North Am* (1993) 77:1205–17. doi: 10.1016/S0025-7125(16)30188-2
3. Hayman J. Mycobacterium Ulcerans: An Infection From Jurassic Time? *Lancet* (1984) 324:1015–6. doi: 10.1016/S0140-6736(84)91110-3
4. Koch R. *Die Ätiologie Der Tuberkulose.* Berlin: Robert Koch-Institut (2010).
5. Hinshaw C, Feldman WH, Pfuetze KH. Treatment of Tuberculosis With Streptomycin: A Summary of Observations on One Hundred Cases. *J Am Med Assoc* (1946) 132:778–82. doi: 10.1001/jama.1946.02870480024007
6. Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. *Ann Am Thorac Soc* (2015) 12:1749–59. doi: 10.1513/AnnalsATS.201509-632PS
7. Iseman MD. Tuberculosis Therapy: Past, Present and Future. *Eur Respir J* (2002) 20:87S. doi: 10.1183/09031936.02.00309102
8. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis* (2016) 63:853–67. doi: 10.1093/cid/ciw566
9. Haas MK, Belknap RW. Updates in the Treatment of Active and Latent Tuberculosis. *Semin Respir Crit Care Med* (2018) 39:297–309. doi: 10.1055/s-0038-1660863
10. Who. *Global Tuberculosis Report - 2021.* Geneva, Switzerland: WHo (2021).
11. Tobin DM. Host-Directed Therapies for Tuberculosis. *Cold Spring Harbor Perspect Med* (2015) 5:a021196. doi: 10.1101/cshperspect.a021196
12. Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, et al. Adjunctive Host-Directed Therapies for Pulmonary Tuberculosis: A Prospective, Open-Label, Phase 2, Randomised Controlled Trial. *Lancet Respir Med* (2021) 9:897–908. doi: 10.1016/S2213-2600(20)30448-3
13. Flynn JL, Chan J. Tuberculosis: Latency and Reactivation. *Infect Immun* (2001) 69:4195–201. doi: 10.1128/IAI.69.7.4195-4201.2001
14. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: What We Don't Know Can, and Does, Hurt Us. *Science (New York NY)* (2010) 328:852–6. doi: 10.1126/science.1184784
15. Dannenberg AMJr., Rook G. Pathogenesis of Pulmonary Tuberculosis: An Interplay of Tissue-Damaging and Macrophage-Activating Immune Responses—Dual Mechanisms That Control Bacillary Multiplication. In: *Tuberculosis.* Washington, DC: Clinical and Diagnostic Laboratory Immunology (1994). p. 459–83.
16. Ernst JD. The Immunological Life Cycle of Tuberculosis. *Nat Rev Immunol* (2012) 12:581–91. doi: 10.1038/nri3259
17. Van Der Meide PH, Schellekens H. Cytokines and the Immune Response. *Biotherapy* (1996) 8:243–9. doi: 10.1007/BF01877210
18. Zeng G, Zhang G, Chen X. Th1 Cytokines, True Functional Signatures for Protective Immunity Against TB? *Chin Soc Immunol* (2018) 15(3):206–15. doi: 10.1038/cmi.2017.113
19. Essone PN, Leboueny M, Maloupazoa Siawaya AC, Alame-Emane AK, Aboumegone Biyogo OC, Dapnet Tadatsin PH, et al. M. Tuberculosis Infection and Antigen Specific Cytokine Response in Healthcare Workers Frequently Exposed to Tuberculosis. *Sci Rep* (2019) 9:8201. doi: 10.1038/s41598-019-44294-0
20. Orme IM, Robinson RT, Cooper AM. The Balance Between Protective and Pathogenic Immune Responses in the TB-Infected Lung. *Nat Immunol* (2015) 16:57–63. doi: 10.1038/ni.3048

21. Gallegos AM, Van Heijst JWJ, Samstein M, Su X, Pamer EG, Glickman MS. A Gamma Interferon Independent Mechanism of CD4 T Cell Mediated Control of M. Tuberculosis Infection *In Vivo*. *PloS Pathog* (2011) 7: e1002052. doi: 10.1371/journal.ppat.1002052

22. Lyadova IV, Panteleev AV. Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers. *Mediators Inflamm* (2015) 2015:13. doi: 10.1155/2015/854507

23. Nikitina IY, Panteleev AV, Sosunova EV, Karpina NL, Bagdasarian TR, Burmistrova IA, et al. Antigen-Specific IFN-γ Responses Correlate with the Activity of M. tuberculosis Infection but Are Not Associated with the Severity of Tuberculosis Disease. *J Immunol Res* (2016) 2016:9. doi: 10.1155/2016/7249369

24. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated Tuberculosis in Interferon Gamma Gene-Distrupted Mice. *J Exp Med* (1993) 178:2243–7. doi: 10.1084/jem.178.6.2243

25. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An Essential Role for Interferon 7 in Resistance to Mycobacterium Tuberculosis Infection. *J Exp Med* (1993) 178(6):2249–54. doi: 10.1084/jem.178.6.2249

26. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T Cells Promote Rather Than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition. *J Immunol (Baltimore Md 1950)* (2011) 186:1598–607. doi: 10.4049/jimmunol.1003304

27. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, et al. CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium Tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. *PloS Pathog* (2016) 12: e1005667–e1005667. doi: 10.1371/journal.ppat.1005667

28. Torrado E, Cooper AM. IL-17 and Th17 Cells in Tuberculosis. *Cytokine Growth Factor Rev* (2010) 21:455–62. doi: 10.1016/j.cytogfr.2010.10.004

29. Okamoto Yoshida Y, Umemura M, Yahagi A, O'brien RL, Ikuta K, Kishihara K, et al. Essential Role of IL-17A in the Formation of a Mycobacterial Infection-Induced Granuloma in the Lung. *J Immunol* (2010) 184:4414–22. doi: 10.4049/jimmunol.0903332

30. Erdmann H, Behrends J, Ritter K, Hölscher A, Volz J, Rosenkrands I, et al. The Increased Protection and Pathology in Mycobacterium Tuberculosis-Infected IL-27R-Alpha-Deficient Mice Is Supported by IL-17A and Is Associated With the IL-17A-Induced Expansion of Multifunctional T Cells. *Mucosal Immunol* (2018) 11:1168–80. doi: 10.1038/s41385-018-0026-3

31. Dai WJ, Köhler G, Brombacher F. Both Innate and Acquired Immunity to Listeria Monocytogenes Infection Are Increased in IL-10-Deficient Mice. *J Immunol* (1997) 158:2259.

32. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, Mcgavern DB, Oldstone MBA. Interleukin-10 Determines Viral Clearance or Persistence In Vivo. *Nat Med* (2006) 12:1301–9. doi: 10.1038/nm1492

33. Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, Gonzalez-Juarrero M. Lack of IL-10 Alters Inflammatory and Immune Responses During Pulmonary Mycobacterium Tuberculosis Infection. *Tuberculosis (Edinb)* (2009) 89:149–57. doi: 10.1016/j.tube.2009.01.001

34. Redford PS, Boonstra A, Read S, Pitt J, Graham C, Stavropoulos E, et al. Enhanced Protection to Mycobacterium Tuberculosis Infection in IL-10-Deficient Mice Is Accompanied by Early and Enhanced Th1 Responses in the Lung. *Eur J Immunol* (2010) 40:2200–10. doi: 10.1002/eji.201040433

35. Neyer LE, Grunig G, Fort M, Remington JS, Rennick D, Hunter CA. Role of Interleukin-10 in Regulation of T-Cell-Dependent and T-Cell-Independent Mechanisms of Resistance to Toxoplasma Gondii. *Infect Immun* (1997) 65:1675–82. doi: 10.1128/iai.65.5.1675-1682.1997

36. Holscher C, Mohrs M, Dai WJ, Kohler G, Ryffel B, Schaub GA, et al. Tumor Necrosis Factor Alpha-Mediated Toxic Shock in Trypanosoma Cruzi-Infected Interleukin 10-Deficient Mice. *Infect Immun* (2000) 68:4075–83. doi: 10.1128/IAI.68.7.4075-4083.2000

37. North RJ. Mice Incapable of Making IL-4 or IL-10 Display Normal Resistance to Infection With Mycobacterium Tuberculosis. *Clin Exp Immunol* (1998) 113:55–8. doi: 10.1046/j.1365-2249.1998.00636.x

38. Beamer GL, Flaherty DK, Assogba BD, Stromberg P, Gonzalez-Juarrero M, De Waal Malefyt R, et al. Interleukin-10 Promotes Mycobacterium Tuberculosis Disease Progression in CBA/J Mice. *J Immunol* (2008) 181:5545–50. doi: 10.4049/jimmunol.181.8.5545

39. Demangel C, Bertolino P, Britton WJ. Autocrine IL-10 Impairs Dendritic Cell (DC)-Derived Immune Responses to Mycobacterial Infection by Suppressing DC Trafficking to Draining Lymph Nodes and Local IL-12 Production. *Eur J Immunol* (2002) 32:994–1002. doi: 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.0.CO;2-6

40. Turner J, Gonzalez-Juarrero M, Ellis DL, Basaraba RJ, Kipnis A, Orme IM, et al. *In Vivo* IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice. *J Immunol* (2002) 169:6343. doi: 10.4049/jimmunol.169.11.6343

41. Schreiber T, Ehlers S, Heitmann L, Rausch A, Mages J, Murray PJ, et al. Autocrine IL-10 Induces Hallmarks of Alternative Activation in Macrophages and Suppresses Antituberculosis Effector Mechanisms Without Compromising T Cell Immunity. *J Immunol* (2009) 183:1301–12. doi: 10.4049/jimmunol.0803567

42. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, et al. Development of Th1-Type Immune Responses Requires the Type I Cytokine Receptor TCCR. *Nature* (2000) 407:916–20. doi: 10.1038/35038103

43. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 Is Required for the Initiation of Th1 Responses and Resistance to L. Major Infection. *Immunity* (2001) 15:569–78. doi: 10.1016/S1074-7613(01)00206-0

44. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment. *J Immunol* (2003) 170:4886. doi: 10.4049/jimmunol.170.10.4886

45. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27r (WSX-1) Is Required to Suppress T Cell Hyperactivity During Infection. *Immunity* (2003) 19:645–55. doi: 10.1016/S1074-7613(03)00300-5

46. Artis D, Johnson LM, Joyce K, Saris C, Villarino A, Hunter CA, et al. Cutting Edge: Early IL-4 Production Governs the Requirement for IL-27-WSX-1 Signaling in the Development of Protective Th1 Cytokine Responses Following *Leishmania major* Infection. *J Immunol* (2004) 172:4672. doi: 10.4049/jimmunol.172.8.4672

47. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 Limits Autoimmune Encephalomyelitis by Suppressing the Development of Interleukin 17-Producing T Cells. *Nat Immunol* (2006) 7:929–36. doi: 10.1038/ni1375

48. Hölscher C, Hölscher A, Rückerl D, Yoshimoto T, Yoshida H, Mak T, et al. The IL-27 Receptor Chain WSX-1 Differentially Regulates Antibacterial Immunity and Survival During Experimental Tuberculosis. *J Immunol* (2005) 174:3534–44. doi: 10.4049/jimmunol.174.6.3534

49. Gearing DP, Cosman D. Homology of the P40 Subunit of Natural Killer Cell Stimulatory Factor (NKSF) With the Extracellular Domain of the Interleukin-6 Receptor. *Cell* (1991) 66:9–10. doi: 10.1016/0092-8674(91)90131-H

50. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a Heterodimeric Cytokine Composed of EBI3 and P28 Protein, Induces Proliferation of Naive CD4+ T Cells. *Immunity* (2002) 16:779–90. doi: 10.1016/S1074-7613(02)00324-2

51. Jones LL, Vignali D. Molecular Interactions Within the IL-6/IL-12 Cytokine/ Receptor Superfamily. *Immunologic Res* (2011) 51:5–14. doi: 10.1007/s12026-011-8209-y

52. Abdalla AE, Li Q, Xie L, Xie J. Biology of IL-27 and Its Role in the Host Immunity Against Mycobacterium Tuberculosis. *Int J Biol Sci* (2015) 11:168–75. doi: 10.7150/ijbs.10464

53. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27. *J Immunol* (2004) 172:2225. doi: 10.4049/jimmunol.172.4.2225

54. Lucas S, Ghilardi N, Li J, De Sauvage FJ. IL-27 Regulates IL-12 Responsiveness of Naive CD4+ T Cells Through Stat1-Dependent and -Independent Mechanisms. *Proc Natl Acad Sci USA* (2003) 100:15047–52. doi: 10.1073/pnas.2536517100

55. Villarino AV, Huang E, Hunter CA. Understanding the Pro- and Anti-Inflammatory Properties of IL-27. *J Immunol* (2004) 173:715–20. doi: 10.4049/jimmunol.173.2.715

56. Villarino AV, Hunter CA. Biology of Recently Discovered Cytokines: Discerning the Pro- and Anti-Inflammatory Properties of Interleukin-27. *Arthritis Res Ther* (2004) 6:225–33. doi: 10.1186/ar1227

57. Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production From Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation. *J Immunol* (2007) 179:4415. doi: 10.4049/jimmunol.179.7.4415

58. Diveu C, Mcgeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 Blocks RORc Expression to Inhibit Lineage Commitment of Th17 Cells. *J Immunol* (2009) 182:5748–56. doi: 10.4049/jimmunol.0801162

59. Do JS, Visperas A, Sanogo YO, Bechtel JJ, Dvorina N, Kim S, et al. An IL-27/Lag3 Axis Enhances Foxp3+ Regulatory T Cell-Suppressive Function and Therapeutic Efficacy. *Mucosal Immunol* (2016) 9:137–45. doi: 10.1038/mi.2015.45

60. Do J, Kim D, Kim S, Valentin-Torres A, Dvorina N, Jang E, et al. Treg-Specific IL-27rα Deletion Uncovers a Key Role for IL-27 in Treg Function to Control Autoimmunity. *Proc Natl Acad Sci USA* (2017) 114:10190–5. doi: 10.1073/pnas.1703100114

61. Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, et al. Cutting Edge: IL-27 Induces the Transcription Factor C-Maf, Cytokine IL-21, and the Costimulatory Receptor ICOS That Coordinately Act Together to Promote Differentiation of IL-10-Producing Tr1 Cells. *J Immunol* (2009) 183:797–801. doi: 10.4049/jimmunol.0901233

62. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The Aryl Hydrocarbon Receptor Interacts With C-Maf to Promote the Differentiation of Type 1 Regulatory T Cells Induced by IL-27. *Nat Immunol* (2010) 11:854–61. doi: 10.1038/ni.1912

63. Rückerl D, Hessmann M, Yoshimoto T, Ehlers S, Hölscher C. Alternatively Activated Macrophages Express the IL-27 Receptor Alpha Chain WSX-1. *Immunobiology* (2006) 211:427–36. doi: 10.1016/j.imbio.2006.05.008

64. Sodenkamp J, Behrends J, Förster I, Müller W, Ehlers S, Hölscher C. Gp130 on Macrophages/Granulocytes Modulates Inflammation During Experimental Tuberculosis. *Eur J Cell Biol* (2011) 90:505–14. doi: 10.1016/j.ejcb.2010.10.010

65. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, et al. IL-27 Acts on DCs to Suppress the T Cell Response and Autoimmunity by Inducing Expression of the Immunoregulatory Molecule CD39. *Nat Immunol* (2013) 14:1054–63. doi: 10.1038/ni.2695

66. Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, Desauvage F, et al. IL-27 Signaling Compromises Control of Bacterial Growth in Mycobacteria-Infected Mice. *J Immunol* (2004) 173:7490–6. doi: 10.4049/jimmunol.173.12.7490

67. Torrado E, Fountain JJ, Liao M, Tighe M, Reiley WW, Lai RP, et al. Interleukin 27R Regulates CD4+ T Cell Phenotype and Impacts Protective Immunity During Mycobacterium Tuberculosis Infection. *J Exp Med* (2015) 212:1449–63. doi: 10.1084/jem.20141520

68. Saunders BM, Britton WJ. Life and Death in the Granuloma: Immunopathology of Tuberculosis. *Immunol Cell Biol* (2007) 85:103–11. doi: 10.1038/sj.icb.7100027

69. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection. *J Immunol* (2002) 168:4620–7. doi: 10.4049/jimmunol.168.9.4620

70. Algood HM, Lin PL, Flynn JL. Tumor Necrosis Factor and Chemokine Interactions in the Formation and Maintenance of Granulomas in Tuberculosis. *Clin Infect Dis* (2005) 41:S189–193. doi: 10.1086/429994

71. Schreiber T, Ehlers S, Aly S, Hölscher A, Hartmann S, Lipp M, et al. Selectin Ligand-Independent Priming and Maintenance of T Cell Immunity During Airborne Tuberculosis. *J Immunol* (2006) 76(2):1131–40. doi: 10.4049/jimmunol.176.2.1131

72. Kahnert A, Höpken UE, Stein M, Bandermann S, Lipp M, Kaufmann SH. Mycobacterium Tuberculosis Triggers Formation of Lymphoid Structure in Murine Lungs. *J Infect Dis* (2007) 195:46–54. doi: 10.1086/508894

73. Maglione PJ, Xu J, Chan J. B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment Upon Pulmonary Challenge With Mycobacterium Tuberculosis. *J Immunol* (2007) 178:7222–34. doi: 10.4049/jimmunol.178.11.7222

74. Linge I, Dyatlov A, Kondratieva E, Avdienko V, Apt A, Kondratieva T. B-Lymphocytes Forming Follicle-Like Structures in the Lung Tissue of Tuberculosis-Infected Mice: Dynamics, Phenotypes and Functional

Activity. *Tuberculosis (Edinb)* (2017) 102:16–23. doi: 10.1016/j.tube.2016.11.005

75. Reiley WW, Shafiani S, Wittmer ST, Tucker-Heard G, Moon JJ, Jenkins MK, et al. Distinct Functions of Antigen-Specific CD4 T Cells During Murine Mycobacterium Tuberculosis Infection. *Proc Natl Acad Sci USA* (2010) 107:19408–13. doi: 10.1073/pnas.1006298107

76. Lindenstrøm T, Knudsen NP, Agger EM, Andersen P. Control of Chronic Mycobacterium Tuberculosis Infection by CD4 KLRG1- IL-2-Secreting Central Memory Cells. *J Immunol* (2013) 190:6311–9. doi: 10.4049/jimmunol.1300248

77. Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, et al. Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31 Against Mycobacterium Tuberculosis Is Highly Dependent on the Antigen Dose. *PloS One* (2009) 4:e5930. doi: 10.1371/journal.pone.0005930

78. Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells. *J Immunol* (2009) 182:8047–55. doi: 10.4049/jimmunol.0801592

79. Derrick SC, Yabe IM, Yang A, Morris SL. Vaccine-Induced Anti-Tuberculosis Protective Immunity in Mice Correlates With the Magnitude and Quality of Multifunctional CD4 T Cells. *Vaccine* (2011) 29:2902–9. doi: 10.1016/j.vaccine.2011.02.010

80. Ritter K, Behrends J, Erdmann H, Rousseau J, Hölscher A, Volz J, et al. Interleukin-23 Instructs Protective Multifunctional CD4 T Cell Responses After Immunization With the Mycobacterium Tuberculosis Subunit Vaccine H1 DDA/TDB Independently of Interleukin-17A. *J Mol Med (Berl)* (2021) 99(11):1585–602. doi: 10.1007/s00109-021-02100-3

81. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of Virulent Mycobacterium Tuberculosis by Reactive Nitrogen Intermediates Produced by Activated Murine Macrophages. *J Exp Med* (1992) 175:1111–22. doi: 10.1084/jem.175.4.1111

82. Seder RA, Darrah PA, Roederer M. T-Cell Quality in Memory and Protection: Implications for Vaccine Design. *Nat Rev Immunol* (2008) 8:247–58. doi: 10.1038/nri2274

83. Dooms H, Kahn E, Knoechel B, Abbas AK. IL-2 Induces a Competitive Survival Advantage in T Lymphocytes. *J Immunol* (2004) 172:5973–9. doi: 10.4049/jimmunol.172.10.5973

84. Sakai S, Kauffman KD, Schenkel JM, Mcberry CC, Mayer-Barber KD, Masopust D, et al. Cutting Edge: Control of Mycobacterium Tuberculosis Infection by a Subset of Lung Parenchyma-Homing CD4 T Cells. *J Immunol* (2014) 192:2965–9. doi: 10.4049/jimmunol.1400019

85. Moguche AO, Shafiani S, Clemons C, Larson RP, Dinh C, Higdon LE, et al. ICOS and Bcl6-Dependent Pathways Maintain a CD4 T Cell Population With Memory-Like Properties During Tuberculosis. *J Exp Med* (2015) 212:715–28. doi: 10.1084/jem.20141518

86. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, et al. Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis. *J Immunol* (2007) 179:3268–75. doi: 10.4049/jimmunol.179.5.3268

87. Hirahara K, Ghoreschi K, Yang XP, Takahashi H, Laurence A, Vahedi G, et al. Interleukin-27 Priming of T Cells Controls IL-17 Production in Trans via Induction of the Ligand PD-L1. *Immunity* (2012) 36:1017–30. doi: 10.1016/j.immuni.2012.03.024

88. Larousserie F, Pflanz S, Coulomb-L'herminé A, Brousse N, Kastelein R, Devergne O. Expression of IL-27 in Human Th1-Associated Granulomatous Diseases. *J Pathol* (2004) 202:164–71. doi: 10.1002/path.1508

89. Yang WB, Liang QL, Ye ZJ, Niu CM, Ma WL, Xiong XZ, et al. Cell Origins and Diagnostic Accuracy of Interleukin 27 in Pleural Effusions. *PloS One* (2012) 7:e40450. doi: 10.1371/journal.pone.0040450

90. Wu YB, Ye ZJ, Qin SM, Wu C, Chen YQ, Shi HZ. Combined Detections of Interleukin 27, Interferon-γ, and Adenosine Deaminase in Pleural Effusion for Diagnosis of Tuberculous Pleurisy. *Chin Med J (Engl)* (2013) 126:3215–21.

91. Xia H, Ye ZJ, Zhou Q, You WJ, Cui A, Wang XJ, et al. IL-27 and IL-27-Producing CD4+ T Cells in Human Tuberculous Pleural Effusion. *Tuberculosis (Edinb)* (2014) 94:579–88. doi: 10.1016/j.tube.2014.07.003

92. Urazova OI, Churina EG, Hasanova RR, Novitskiy VV, Poletika VS. Association Between Polymorphisms of Cytokine Genes and Secretion of IL-12p70, IL-18, and IL-27 by Dendritic Cells in Patients With Pulmonary

Tuberculosis. *Tuberculosis (Edinb)* (2019) 115:56–62. doi: 10.1016/j.tube.2019.02.003

93. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 Induces Regulatory B Cells That Suppress Autoimmune Disease. *Nat Med* (2014) 20:633–41. doi: 10.1038/nm.3554

94. Hasegawa H, Mizoguchi I, Chiba Y, Ohashi M, Xu M, Yoshimoto T. Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family. *Front Immunol* (2016) 7:479. doi: 10.3389/fimmu.2016.00479

95. Crabé S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, et al. The IL-27 P28 Subunit Binds Cytokine-Like Factor 1 to Form a Cytokine Regulating NK and T Cell Activities Requiring IL-6R for Signaling. *J Immunol* (2009) 183:7692–702. doi: 10.4049/jimmunol.0901464

96. Jung JY, Robinson CM. Interleukin-27 Inhibits Phagosomal Acidification by Blocking Vacuolar ATPases. *Cytokine* (2013) 62:202–5. doi: 10.1016/j.cyto.2013.03.010

97. Jung JY, Robinson CM. IL-12 and IL-27 Regulate the Phagolysosomal Pathway in Mycobacteria-Infected Human Macrophages. *Cell Commun Signal* (2014) 12:16. doi: 10.1186/1478-811X-12-16

98. Sharma G, Dutta RK, Khan MA, Ishaq M, Sharma K, Malhotra H, et al. IL-27 Inhibits IFN-γ Induced Autophagy by Concomitant Induction of JAK/PI3 K/Akt/mTOR Cascade and Up-Regulation of Mcl-1 in Mycobacterium Tuberculosis H37Rv Infected Macrophages. *Int J Biochem Cell Biol* (2014) 55:335–47. doi: 10.1016/j.biocel.2014.08.022

99. Lockhart E, Green AM, Flynn JL. IL-17 Production Is Dominated by Gammadelta T Cells Rather Than CD4 T Cells During Mycobacterium Tuberculosis Infection. *J Immunol* (2006) 177:4662–9. doi: 10.4049/jimmunol.177.7.4662

100. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, Rudensky AY, et al. Expansion and Function of Foxp3-Expressing T Regulatory Cells During Tuberculosis. *J Exp Med* (2007) 204:2159–69. doi: 10.1084/jem.20062105

101. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-Specific Regulatory T Cells Delay the Arrival of Effector T Cells in the Lung During Early Tuberculosis. *J Exp Med* (2010) 207:1409–20. doi: 10.1084/jem.20091885

102. Lin PL, Flynn JL. CD8 T Cells and Mycobacterium Tuberculosis Infection. *Semin Immunopathol* (2015) 37:239–49. doi: 10.1007/s00281-015-0490-8

103. Behar SM, Woodworth JS, Wu Y. Next Generation: Tuberculosis Vaccines That Elicit Protective CD8+ T Cells. *Expert Rev Vaccines* (2007) 6:441–56. doi: 10.1586/14760584.6.3.441

104. Boom WH. New TB Vaccines: Is There a Requirement for CD8 T Cells? *J Clin Invest* (2007) 117:2092–4. doi: 10.1172/JCI32933

105. Ottenhoff TH, Kaufmann SH. Vaccines Against Tuberculosis: Where Are We and Where do We Need to Go? *PLoS Pathog* (2012) 8:e1002607. doi: 10.1371/journal.ppat.1002607

106. Ulrichs T, Kosmiadi GA, Trusov V, Jörg S, Pradl L, Titukhina M, et al. Human Tuberculous Granulomas Induce Peripheral Lymphoid Follicle-Like Structures to Orchestrate Local Host Defence in the Lung. *J Pathol* (2004) 204:217–28. doi: 10.1002/path.1628

107. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, et al. Characterization of the Tuberculous Granuloma in Murine and Human Lungs: Cellular Composition and Relative Tissue Oxygen Tension. *Cell Microbiol* (2006) 8:218–32. doi: 10.1111/j.1462-5822.2005.00612.x

108. Sia JK, Georgieva M, Rengarajan J. Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions Between Mycobacterium Tuberculosis and Innate Immune Cells. *J Immunol Res* (2015) 2015:747543. doi: 10.1155/2015/747543

109. Liu CH, Liu H, Ge B. Innate Immunity in Tuberculosis: Host Defense vs Pathogen Evasion. *Cell Mol Immunol* (2017) 14:963–75. doi: 10.1038/cmi.2017.88

110. Robinson CM, O'dee D, Hamilton T, Nau GJ. Cytokines Involved in Interferon-Gamma Production by Human Macrophages. *J Innate Immun* (2010) 2:56–65. doi: 10.1159/000247156

111. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, et al. Enhanced Th1 Activity and Development of Chronic Enterocolitis in Mice Devoid of Stat3 in Macrophages and Neutrophils. *Immunity* (1999) 10:39–49. doi: 10.1016/S1074-7613(00)80005-9

112. Robinson CM, Jung JY, Nau GJ. Interferon-γ, Tumor Necrosis Factor, and Interleukin-18 Cooperate to Control Growth of Mycobacterium Tuberculosis in Human Macrophages. *Cytokine* (2012) 60:233–41. doi: 10.1016/j.cyto.2012.06.012

113. Iyer SS, Ghaffari AA, Cheng G. Lipopolysaccharide-Mediated IL-10 Transcriptional Regulation Requires Sequential Induction of Type I IFNs and IL-27 in Macrophages. *J Immunol* (2010) 185:6599–607. doi: 10.4049/jimmunol.1002041

114. Benes P, Vetvicka V, Fusek M. Cathepsin D–Many Functions of One Aspartic Protease. *Crit Rev Oncol Hematol* (2008) 68:12–28. doi: 10.1016/j.critrevonc.2008.02.008

115. Ritter K, Sodenkamp JC, Hölscher A, Behrends J, Hölscher C. IL-6 Is Not Absolutely Essential for the Development of a TH17 Immune Response After an Aerosol Infection With Mycobacterium Tuberculosis H37rv. *Cells* (2020) 10(1):9. doi: 10.3390/cells10010009

116. Morita Y, Masters EA, Schwarz EM, Muthukrishnan G. Interleukin-27 and Its Diverse Effects on Bacterial Infections. *Front Immunol* (2021) 12:678515. doi: 10.3389/fimmu.2021.678515

117. Seiler P, Aichele P, Bandermann S, Hauser AE, Lu B, Gerard NP, et al. Early Granuloma Formation After Aerosol Mycobacterium Tuberculosis Infection Is Regulated by Neutrophils via CXCR3-Signaling Chemokines. *Eur J Immunol* (2003) 33:2676–86. doi: 10.1002/eji.200323956

118. Eruslanov EB, Lyadova IV, Kondratieva TK, Majorov KB, Scheglov IV, Orlova MO, et al. Neutrophil Responses to Mycobacterium Tuberculosis Infection in Genetically Susceptible and Resistant Mice. *Infect Immun* (2005) 73:1744–53. doi: 10.1128/IAI.73.3.1744-1753.2005

119. Keller C, Hoffmann R, Lang R, Brandau S, Hermann C, Ehlers S. Genetically Determined Susceptibility to Tuberculosis in Mice Causally Involves Accelerated and Enhanced Recruitment of Granulocytes. *Infect Immun* (2006) 74:4295–309. doi: 10.1128/IAI.00057-06

120. Dietrich C, Candon S, Ruemmele FM, Devergne O. A Soluble Form of IL-27rα Is a Natural IL-27 Antagonist. *J Immunol* (2014) 192:5382–9. doi: 10.4049/jimmunol.1303435

121. Wirtz S, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS, et al. Protection From Lethal Septic Peritonitis by Neutralizing the Biological Function of Interleukin 27. *J Exp Med* (2006) 203:1875–81. doi: 10.1084/jem.20060471

122. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The Risk of Tuberculosis Related to Tumour Necrosis Factor Antagonist Therapies: A TBNET Consensus Statement. *Eur Respir J* (2010) 36:1185–206. doi: 10.1183/09031936.00028510

123. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A Study of the Safety, Immunology, Virology, and Microbiology of Adjunctive Etanercept in HIV-1-Associated Tuberculosis. *Aids* (2004) 18:257–64. doi: 10.1097/00002030-200401230-00015

124. Vinhaes CL, Sheikh V, Oliveira-De-Souza D, Wang J, Rupert A, Roby G, et al. An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People With Advanced HIV: A Prospective International Cohort Study. *J Infect Dis* (2021) 223:1275–83. doi: 10.1093/infdis/jiaa484